This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SITC 2021
Presentations
SGN-B7H4V | Preclinical | Poster #854
SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models